National utilization patterns of Mohs micrographic surgery for invasive melanoma and melanoma in situ
| Autor: | Jane Yoo, Cary P. Gross, Kate V. Viola, Payal Patel, Emily F. Stamell, Ryan B. Turner, Kameron S. Rezzadeh, Lou Gonsalves |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Skin Neoplasms medicine.medical_treatment Dermatology Disease-Free Survival Cohort Studies Sex Factors Epidemiology Odds Ratio Surveillance Epidemiology and End Results Mohs surgery Humans Medicine Neoplasm Invasiveness Registries Melanoma neoplasms Aged Neoplasm Staging Retrospective Studies Aged 80 and over business.industry Incidence organic chemicals Carcinoma in situ Wide local excision fungi Age Factors Cancer Retrospective cohort study Middle Aged Mohs Surgery Prognosis medicine.disease Survival Analysis Logistic Models Treatment Outcome Female Lymph Nodes business Carcinoma in Situ |
| Zdroj: | Journal of the American Academy of Dermatology. 72:1060-1065 |
| ISSN: | 0190-9622 |
| Popis: | Background Although wide local excision continues to be commonly used for melanoma treatment, Mohs micrographic surgery (MMS) for the treatment of melanomas remains controversial. Objective We sought to determine national utilization patterns for MMS in the treatment of invasive melanoma and melanoma in situ. Methods A retrospective analysis of patients receiving surgical excision (MMS or wide local excision) for the treatment of invasive melanoma and melanoma in situ was performed using data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program. Results A total of 195,768 melanomas were diagnosed from 2003 through 2009 from the 17 SEER registries. Utilization of MMS for invasive melanoma and melanoma in situ increased by 60% from 2003 to 2008. Of all SEER-captured lesions treated by surgical excision in this time period, 3.5% (6872) were excised by MMS. Limitations Patient insurance status, physician reimbursement practices, and health care provider type were not addressed in this article. Conclusion Use of MMS for melanoma appears to be increasing. Future studies should explore whether this is associated with better outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect